VAXIL Provides Update on USAMRIID and Oral Experiments

By Dr. Matthew Watson

NESS-ZIONA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that further to our press release dated December 3, 2020, in respect to our cooperative research and development agreement (CRADA) with US Army Medical Research Institute of Infectious Diseases (“USAMRIID”), the mice have received two of the three scheduled vaccinations. The third and final vaccine is scheduled to be administered later this week. USAMRIID reports that the mice appear to be fine having responded normally to the injections administered to date and that the experiment is proceeding on schedule. The Company expects that the mice will be “challenged” with the COVID-19 virus in mid-January 2021, after having had the chance to develop an immune response. Vaxil expects to provide a further update at the beginning of February 2021.

Read the original:
VAXIL Provides Update on USAMRIID and Oral Experiments

Related Post

categoriaGlobal News Feed commentoComments Off on VAXIL Provides Update on USAMRIID and Oral Experiments | dataJanuary 3rd, 2021


This author published 3712 posts in this site.


FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.

Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research